Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Preliminary Q4: Earnings Up, Losses Widen

NEW YORK, Jan. 29 (GenomeWeb News) - Cepheid reported preliminary fourth-quarter results today, in which revenues increased amid widened net losses.


The company, which plans to formally announce its fourth quarter earnings Feb. 17, said its revenues increased to $4.9 million for the quarter, up from $3.7 million for the same period of 2002. Net losses meanwhile increased to $4.5 million, from $3.5 million in the year-ago quarter.


Cepheid also said its product sales for 2004 would be between $42 and $46 million, and would be weighted toward the second half of the year. Net loss, it projected, would be between $10.5 and $12.5 million.


Cepheid, of Sunnyvale, Calif, did not say why it was pre-releasing earnings and forecasts.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.